Key Insights

Highlights

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Enrolling By Invitation1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT01346150Unknown

Patients Treated for SCID (1968-Present)

NCT01186913Enrolling By Invitation

Natural History Study of SCID Disorders

Showing all 2 trials

Research Network

Active Sponsors

  • National Center for Advancing Translational Sciences (NCATS)2
  • National Institute of Allergy and Infectious Diseases (NIAID)2
  • Primary Immune Deficiency Treatment Consortium (PIDTC)2
  • Office of Rare Diseases (ORD)1

Top Investigators

Related Conditions

  • Xscid2
  • Reticular Dysgenesis2
  • Omenn Syndrome2
  • Adascid1
  • Ada Scid1

Activity Timeline